In this free webinar, learn how anti-idiotype (anti-ID) antibody development strategies can support sensitive and specific pharmacokinetic and anti-drug antibody assays. The featured speaker will discuss platform selection, common reasons anti-ID programs fail and the development of blocker and non-blocker antibodies. Attendees will also explore case studies showing how different discovery strategies can be matched to specific drug targets.

TORONTO, Nov. 2, 2026 /PRNewswire/ -- Therapeutic antibodies are a rapidly growing class of drugs. Their application areas are not only limited to the standard immunoglobulin G (IgG) format but can also be extended to novel formats, including antibody fragments (scFv, VHH), drug conjugates and bispecifics. This webinar explores platform selection and development strategies for generating high-performance anti-idiotype (anti-ID) antibodies to support pharmacokinetic (PK) and anti-drug antibody (ADA) assays.

To ensure their safety and efficacy, regulatory agencies and pharmaceutical developers rely on two essential types of assays: PK assays and ADA assays. PK measures how a drug is absorbed, distributed, metabolized and eliminated in the body. ADA assays are designed to detect and measure the immunogenicity of an antibody drug after treatment.

Anti-ID antibodies bind to the idiotype, a specific epitope group on the variable region, of another antibody, usually an antibody drug. High-performance anti-IDs are critical for developing sensitive, specific and robust PK and ADA assays to support pre-clinical and clinical studies in drug development programs. High sensitivity and specificity, strong affinity and well-defined epitope-binding specificity are important features for anti-IDs.

Rabbit monoclonal antibodies (mAbs) are known for their high affinity and diversity, making them a valuable source of highly specialized research reagents. The lower homology of the antibody drug to rabbit germline sequences compared with mice suggests that rabbits may generally mount a stronger immune response to an antibody drug than mice. An optimized rabbit B cell cloning platform can support the discovery of high-quality anti-IDs with high sequence diversity and affinity, including blocker and non-blocker antibodies.

Register for this webinar to learn how anti-idiotype antibody development strategies can support sensitive, specific PK and ADA assays.

Join Zhihao Li, Senior Scientist, Antibody Development, GenScript, for the live webinar on Tuesday, November 17, 2026, at 10am EST (4pm CET / EU-Central).

For more information, or to register for this event, visit Platform Selection and Development Strategies for High-Performance Anti-Idiotype Antibody Development – in Just 9 Weeks.

ABOUT XTALKS

Xtalks – The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.

Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what's next.

To learn more about Xtalks, visit www.xtalks.com
For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/

Contact:
Soumya Shashikumar
Tel: +1 (416) 977-6555 x371
Email: skumar@xtalks.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/platform-selection-and-development-strategies-for-high-performance-anti-idiotype-antibody-development--in-just-9-weeks-upcoming-webinar-hosted-by-xtalks-302925610.html

SOURCE Xtalks